These press releases are for business and financial media.
-
- 28 December 2001
- AstraZeneca submits clinical data for IRESSA (ZD1839) – a new class of anti-cancer treatment - in the USA AstraZeneca today announced that it has submitted a clinical data package to the U.S. Food and Drug Administration (FDA) in support of IRESSA (ZD1839) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in patients who have failed on previous chemotherapy regimens. IRESSA has been granted fast track review by the US authorities for this indication.
-
- 21 December 2001
- ASTRAZENECA SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR CASODEX 150 MG FOR THE TREATMENT OF EARLY STAGE PROSTATE CANCER AstraZeneca today announced that a supplemental New Drug Application (sNDA) has been filed with the U.S. Food and Drug Administration (FDA) for the company’s oral, once-daily hormonal medication Casodex (bicalutamide 150mg) for the treatment of early stage non-metastatic prostate cancer.
-
- 20 December 2001
- AstraZeneca and Lilly Collaborate on Clinical Trial Programmes To Study IRESSA™ (ZD1839) In Combination With Gemzar® (Gemcitabine) For the Treatment of Various Cancers AstraZeneca and Eli Lilly Company today announced their clinical collaboration to evaluate the benefits of IRESSA™ (ZD1839) in combination with Gemzar® (gemcitabine) for the treatment of various cancers. The clinical collaboration, which will be jointly funded by both companies, will initially assess the combination of the two treatments as part of a Phase II clinical trial programme involving patients with advanced stage non-small cell lung cancer (NSCLC) and bladder cancer. The companies also plan to
-
- 11 December 2001
- NEW DATA ON ARIMIDEX® HERALD ENTRY INTO EARLY BREAST CANCER AstraZeneca today announced that new data presented at the San Antonio Breast Cancer Meeting demonstrate for the first time that leading aromatase inhibitor Arimidex ® is significantly more effective and has important tolerability benefits compared with the current gold standard, tamoxifen, as an adjuvant treatment in postmenopausal women with early breast cancer.
-
- 03 December 2001
- ASTRAZENECA'S COMMERCIAL STRENGTH AND EXCELLENT PIPELINE TO DRIVE GROWTH AND ENSURE SUCCESS IN COMING YEARS AstraZeneca today presents a business update to a meeting of analysts in London.Download the press release and the pipeline table
-
- 26 November 2001
- ASTRAZENECA RECEIVES SIX MONTHS’ MARKET EXCLUSIVITY FOR ZESTRIL® (LISINOPRIL) AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) granted six months’ market exclusivity for the ACE inhibitor ZESTRIL® (lisinopril) after the company complied with the FDA’s written request for information on the use of the medication in children.
-
- 01 November 2001
- FIRST PHASE II STUDY RESULTS SHOW ANTI-TUMOUR ACTIVITY WITH IRESSA™ IN ADVANCED NON-SMALL CELL LUNG CANCER Preliminary data from the first pivotal phase II trial, presented today at the 12th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Miami, USA , demonstrate that when used as a second or third-line treatment, IRESSA™ leads to overall disease control in more than 50 per cent of unselected [1] patients with advanced non-small cell lung cancer (NSCLC) who have failed previous platinum-based therapy.
-
- 31 October 2001
- ASTRAZENECA WINS GENERIC OMEPRAZOLE CASE IN NORWAY AstraZeneca today announced that the Oslo Byrett (Oslo City Court) in Norway found that a generic omeprazole product marketed by Scandinavian Pharmaceuticals-Generics AB (Scand Pharm) infringes AstraZeneca’s formulation patent for omeprazole, the substance used in Losec. At the same time, the Court declared AstraZeneca’s omeprazole formulation patent valid.
-
- 24 October 2001
- ASTRAZENECA PLC THIRD QUARTER RESULTS 2001 Download the narrative and the figures.
-
- 23 October 2001
- PRILOSEC US LITIGATION AstraZeneca today announced that it had received confirmation that its pending litigation to defend its patents associated with Prilosec in the US will go to trial in a case to be heard by Judge Jones commencing in New York on December 5th 2001.
-
- 19 October 2001
- ZD1839 IRESSA DATA AstraZeneca is encouraged by the positive results from IDEAL 1 ( I RESSA D ose E valuation in A dvanced L ung cancer), the first pivotal study of ZD1839 (IRESSA) in non-small-cell-lung-cancer (NSCLC) and looks forward to the presentation of these phase II data at the 12th AACR-NCI-EORTC International Conference on "Molecular Targets and Cancer Therapeutics" in Miami, USA. Whilst the abstract of the data is available on www.aacr.org , the full results from IDEAL 1 will not be presented until Thursday,
-
- 09 October 2001
- NEXIUM® OUTPERFORMS LANSOPRAZOLE IN FIRST HEAD-TO-HEAD CLINICAL TRIALS Stanhope Gate, London, UK - The long-awaited results of head-to-head clinical trials between AstraZeneca’s newest proton pump inhibitor (PPI) therapy, Nexium® (esomeprazole), and its principal competitor, lansoprazole, were released today at the United European Gastroenterology Week (UEGW) in Amsterdam.
-
- 28 September 2001
- Government Minister opens 45 million GBP new science facility at AstraZeneca R&D Charnwood AstraZeneca announces the opening of one of Europe’s most technically advanced Pharmaceutical Development Facilities at its R&D site at Charnwood, near Loughborough, Leics. The 45 million GBP state-of-the-art facility is dedicated to providing supplies of potential new medicines for worldwide clinical trials and to developing the manufacturing processes required for eventual transfer to large-scale production.
-
- 17 September 2001
- ASTRAZENECA RECEIVES FIRST REGULATORY APPROVALS FOR CASODEX™ 150MG IN EARLY PROSTATE CANCER AstraZeneca has gained its first approval for Casodex™ (bicalutamide) 150mg for the treatment of early stages of prostate cancer in the United Kingdom. Casodex™ 150mg represents the first once daily drug therapy available for treatment of the early stages of this disease.
-
- 26 July 2001
- ASTRAZENECA PLC HALF YEAR RESULTS 2001 Download the narrative and the figures .
-
- 25 July 2001
- ASTRAZENECA APPOINTS NEW NON - EXECUTIVE DIRECTOR AstraZeneca PLC announces the appointment, with effect from 24 September 2001, of Jane E. Henney, M.D. as a non-executive Director.
-
- 10 July 2001
- NEW DATA SUPPORT THE EFFICACY AND SAFETY OF THE NOVEL ORAL ANTICOAGULANT EXANTA® The presentation of a wide range of data at the 18th International Society on Thrombosis and Haemostasis meeting (ISTH) in Paris this week, provided new evidence to support the efficacy and safety of Exanta®, which is set to be the first new oral anticoagulant since warfarin was introduced over 50 years ago.
-
- 26 June 2001
- ASTRAZENECA SUBMITS ITS NEW SUPERSTATIN, CRESTOR, FOR REGULATORY APPROVAL IN THE US & EUROPE. DEVELOPMENT OF VIOZAN COPD TREATMENT TO BE DISCONTINUED; RESOURCES TO BE REALLOCATED TO MORE PROMISING PRODUCTS IN R&D PIPELINE AstraZeneca announced today that the regulatory file for Crestor (rosuvastatin), a new statin for lipid lowering, has been submitted in the USA and Europe and that it had discontinued further development of Viozan, the D2B2 agonist for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
-
- 20 June 2001
- ASTRAZENECA OBTAINS APPROVAL FOR ZOMIG® MIGRAINE TREATMENT IN JAPAN AstraZeneca today received approval to market Zomig® for migraine treatment in Japan - the first, second generation triptan type of medicine to be approved there.
-
- 02 May 2001
- ASTRAZENECA RECEIVES SIX MONTHS' MARKET EXCLUSIVITY FOR PRILOSEC® AstraZeneca today announced that the US Food and Drug Administration (FDA) granted six months' market exclusivity for Prilosec® (omeprazole), after the company complied with the FDA's formal request for information on the use of the prescription medication in children. The additional six months' exclusivity will be added to all of the relevant patents for Prilosec®.
-
- 02 May 2001
- COURT DENIES GENERIC'S APPLICATION FOR SUMMARY JUDGEMENT ON PRILOSEC® PATENT AstraZeneca announced today that the United States District Court for the Southern District of New York has denied a summary judgement motion filed by Reddy-Cheminor alleging invalidity of a patent (US patent no:4,255,431) at issue in a lawsuit. The patent relates to omeprazole, the active ingredient in Prilosec®, a treatment for stomach acid disorders.
-
- 28 April 2001
- ASTRAZENECA OPENS NEW $100M PHARMACEUTICALS PLANT IN CHINA AstraZeneca today inaugurates a new $100m manufacturing plant in China - one of the largest investments by a Western pharmaceuticals company in the People's Republic.
-
- 26 April 2001
- ASTRAZENECA PLC FIRST QUARTER RESULTS 2001, 26 April 2001 Download the narrative and the figures .
-
- 25 April 2001
- ASTRAZENECA INVESTS $10M IN BANGALORE LABORATORIES AstraZeneca PLC today announced plans for investment in India to create a centre of excellence at its facility in Bangalore for the discovery and development of new medicines of importance to the developing world.
-
- 23 April 2001
- ASTRAZENECA FILES LAWSUIT AGAINST APOTEX CORPORATION AND TORPHARM FOR PATENT INFRINGEMENT AstraZeneca confirmed today that it has filed a lawsuit in Illinois against Apotex Corporation and Torpharm for patent infringement.
-
- 09 April 2001
- RESULTS FROM LARGEST EVER PROSTATE CANCER STUDY SHOW ASTRAZENECA'S CASODEX ALMOST HALVES RISK OF DISEASE PROGRESSION First analysis of results from the largest ever study of its type announced today at the 16th annual meeting of the European Association of Urology shows that AstraZeneca's treatment, Casodex™ (bicalutamide) 150mg, cuts the risk of disease progression by almost half in patients with localised or locally advanced prostate cancer.
-
- 30 March 2001
- ASTRAZENECA SUBMITS NEW DRUG APPLICATION (NDA) TO FDA FOR NEW TYPE OF BREAST CANCER TREATMENT AstraZeneca today announced the submission of a new drug application (NDA), requesting Priority Review with the U.S. Food and Drug Administration (FDA) for Faslodex™, for treatment of locally advanced or metastatic breast cancer in postmenopausal women who have previously progressed following hormonal therapy.
-
- 29 March 2001
- ASTRAZENECA'S ENTOCORT™ (budesonide modified-release capsules) GRANTED PRIORITY REVIEW STATUS BY THE FDA AstraZeneca today announced that its New Drug Application (NDA) for Entocort™ (budesonide modified-release capsules) has been filed for the treatment of mild to moderate active Crohn's disease. The application, which was submitted to the Food and Drug Administration (FDA) on January 24, 2001, has been granted priority review status by the agency.
-
- 28 March 2001
- ASTRAZENECA MAKES FIRST REGULATORY SUBMISSION FOR USE OF 'CASODEX™' 150MG IN EARLY PROSTATE CANCER AstraZeneca today submitted a dossier to the Medicines Control Agency, the UK regulatory authority, for the use of Casodex™ (bicalutamide) 150mg in the treatment of localised and locally advanced prostate cancer - Early Prostate Cancer (EPC). This is the first submission, two years earlier than the planned date, and will be followed by subsequent submissions around the world, with the objective of providing clinicians and patients with an additional treatment option for the early stages of prostate cancer.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 20-Nov-2009 22:46 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
